Registry of Lobbyists
Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
Version 2 of 5 (2007-05-07 to 2007-11-19) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Consultant lobbyist name: | Elsa Koutsavakis Lobbyist business address |
| Consulting firm: |
GLOBAL PUBLIC AFFAIRS
50 O'Connor Street Suite 901 Ottawa, ON K1P 6L2 Canada |
| Position: | Research Consultant |
| Telephone number: | 613-783-3438 |
| Fax number: | 613-782-2428 |
| Former public office holder: | No |
| Payment is contingent on the success of the undertaking: | No |
| Client: |
ALLERGAN CANADA
110 COCHRANE ROAD MARKHAM, ON L3R 9S1 Canada |
| Telephone number: | 905-940-7164 |
| Client Representative: |
MARK
GILMOUR
|
| The client is a subsidiary of the following parent companies: |
ALLERGAN INC.
PO BOX 19534 IRVINE, CA United States of America 92623 |
| Coalition: | The client is not a coalition. |
| Subsidiary: | The client does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Individual, organization or corporation: | The client's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the client funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Health Canada (HC), Industry Canada, Patented Medicine Prices Review Board (PMPRB) | ||||
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||
| Subject Matter: Areas of Concern: | Consumer Issues, Health, Industry, Intellectual Property, Science and Technology | ||||
Details Regarding the Identified Subject Matter
|
|||||